Chinese President Xi Jinping wrote a letter to his Pakistani counterpart Arif Alvi and wished him a quick recovery from coronavirus.
President Alvi along with Defence Minister Pervaiz Khattak tested positive for Covid-19 on March 29.
“I have tested positive for Covid-19. May Allah have mercy on all Covid affectees. Had 1st dose of vaccine but antibodies start developing after 2nd dose that was due in a week. Please continue to be careful,” the president wrote on his official Twitter handle.
وازا مرضت فھوا یشفین
— Dr. Arif Alvi (@ArifAlvi) March 29, 2021
اور جب میں بیمار ہوتا ہوں تو وہی شفا دیتا ہے
I have tested positive for Covid-19. May Allah have mercy on all Covid affectees. Had 1st dose of vaccine، but antibodies start developing after 2nd dose that was due in a week. Please continue to be careful.
Chinese Ambassador to Pakistan Nong Rong said in a tweet on Friday that, “President Xi sent a letter to Hon President Arif Alvi & wished him a speedy recovery.”
President Xi stressed that China would always stand with Pakistan to jointly fight against the Covid-19 pandemic and make joint efforts to build a closer China-Pakistan community with shared future, he added.
President Xi sent a letter to Hon. President @ArifAlvi &wished him a speedy recovery. President Xi stressed that China would always stand with Pakistan to jointly fight against the COVID-19 pandemic &make joint efforts to build a closer China-Pakistan community with shared future
— Nong Rong (@AmbNong) April 2, 2021
Pakistan started the vaccination campaign in February this year with doses donated by the government of China. The campaign started with frontline healthcare workers and then inoculation of the senior citizens in the second phase.
Minister for Planning Asad Umar, who leads the government anti-pandemic strategy, had said: “We will be getting the bulk vaccine by mid-April from CanSino from which three million vaccine doses can be made.”
COMMENTS
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ